. Author manuscript; available in PMC: 2020 Aug 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2019 Mar 27;17(9):1655–1668.e3. doi: 10.1016/j.cgh.2019.03.037

Table 4.

Scenarios of applying therapeutic drug monitoring of biological therapy in patients with inflammatory bowel disease.

Statement	Vote agreement, %
*A. Anti-TNFs*
1. It is appropriate to order drug/antibody concentration testing, in responders at the end of induction for all anti-TNFs.	92 (12/13)
2. It is appropriate to order drug/antibody concentration testing at least once during maintenance for patients on all anti-TNFs.	100 (13/13)
3. It is appropriate to order drug/antibody concentration testing of anti-TNFs at the end of induction in primary non-responders.	100 (13/13)
4. It is appropriate to order drug/antibody concentration testing for all anti-TNFs, in patients with confirmed secondary loss of response.	100 (13/13)
*B. Vedolizumab*
5. It is appropriate to order drug/antibody concentration testing for vedolizumab, in responders at the end of induction.	15 (2/13)^a
6. It is appropriate to order drug/antibody concentration testing at least once during maintenance for patients on vedolizumab.	46 (6/13)^a
7. It is appropriate to order drug/antibody concentration testing for vedolizumab in non-responders at the end of induction.	92 (12/13)
8. It is appropriate to order drug/antibody concentration testing for vedolizumab, in patients with confirmed secondary loss of response.	83 (10/12)^a
*C. Ustekinumab*
9. It is appropriate to order drug/antibody concentration testing for ustekinumab, in responders at the end of induction.	39 (5/13)^a
10. It is appropriate to order drug/antibody concentration testing at least once during maintenance for patients on ustekinumab.	31 (4/13)^a
11. It is appropriate to order drug/antibody concentration testing for ustekinumab in non-responders at the end of induction (at 8 weeks).	92 (12/13)
12. It is appropriate to order drug/antibody concentration testing for ustekinumab, in patients with confirmed secondary loss of response.	83 (10/12)^a

After a second round of voting.

TNF: tumor necrosis factor